Top-Rated StocksTop-RatedNASDAQ:ITCI Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News $63.21 +1.89 (+3.08%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$60.76▼$63.2650-Day Range$54.15▼$66.4452-Week Range$42.01▼$66.56Volume472,038 shsAverage Volume623,634 shsMarket Capitalization$6.06 billionP/E RatioN/ADividend YieldN/APrice Target$74.45 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Intra-Cellular Therapies MarketRank™ ForecastAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside3.2% Downside$61.17 Price TargetShort InterestBearish3.71% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.54Based on 10 Articles This WeekInsider TradingSelling Shares$5.83 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.32) to ($1.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector232nd out of 985 stocksPharmaceutical Preparations Industry109th out of 483 stocks 2.4 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $61.17, Intra-Cellular Therapies has a forecasted downside of 3.2% from its current price of $63.21.Amount of Analyst CoverageIntra-Cellular Therapies has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.71% of the outstanding shares of Intra-Cellular Therapies have been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Intra-Cellular Therapies has recently increased by 21.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.23. Previous Next 2.0 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Intra-Cellular Therapies this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ITCI on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,831,627.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions86.95% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($2.32) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -26.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -26.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 9.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Intra-Cellular Therapies (NASDAQ:ITCI) StockIntra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.Read More Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address ITCI Stock News HeadlinesJune 5, 2023 | finance.yahoo.comITCI Jul 2023 65.000 callJune 5, 2023 | msn.comJP Morgan Maintains Intra-Cellular Therapies (ITCI) Overweight RecommendationJune 6, 2023 | Edge On The Street (Ad)ChatGPT Is Already "Old School"As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.June 5, 2023 | markets.businessinsider.comAnalyst Expectations for Intra-Cellular Therapies's FutureJune 5, 2023 | finance.yahoo.comIntra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceMay 31, 2023 | finance.yahoo.comIntra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual MeetingMay 31, 2023 | finance.yahoo.comIntra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual MeetingMay 28, 2023 | americanbankingnews.comBrokerages Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $74.45June 6, 2023 | Edge On The Street (Ad)How to Invest in AI's Fast-Growing MarketThe AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.May 17, 2023 | americanbankingnews.comHead to Head Analysis: Intra-Cellular Therapies (NASDAQ:ITCI) and Arbutus Biopharma (NASDAQ:ABUS)May 8, 2023 | msn.comMizuho Maintains Intra-Cellular Therapies (ITCI) Buy RecommendationMay 8, 2023 | finance.yahoo.comInvesting in Intra-Cellular Therapies (NASDAQ:ITCI) three years ago would have delivered you a 208% gainMay 8, 2023 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $76.00May 8, 2023 | americanbankingnews.comCantor Fitzgerald Raises Intra-Cellular Therapies (NASDAQ:ITCI) Price Target to $90.00May 5, 2023 | msn.comCantor Fitzgerald Maintains Intra-Cellular Therapies (ITCI) Overweight RecommendationMay 5, 2023 | msn.comRBC Capital Maintains Intra-Cellular Therapies (ITCI) Outperform RecommendationMay 4, 2023 | finance.yahoo.com‘Don’t let the earnings beats fool you’: Morgan Stanley advises investors to temper their optimism amidst a looming recession — use these 2 stocks for protectionMay 4, 2023 | finanznachrichten.deIntra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 4, 2023 | msn.comRecap: Intra-Cellular Therapies Q1 EarningsMay 4, 2023 | msn.comIntra-Cellular Therapies Q1 2023 Earnings PreviewMay 4, 2023 | finance.yahoo.comIntra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 3, 2023 | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $74.00 Average Price Target from AnalystsApril 26, 2023 | finance.yahoo.comIntra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and WebcastApril 25, 2023 | americanbankingnews.comSVB Leerink Comments on Intra-Cellular Therapies, Inc.'s FY2027 Earnings (NASDAQ:ITCI)April 22, 2023 | americanbankingnews.comMorgan Stanley Begins Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)April 22, 2023 | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Director Sells $630,000.00 in StockApril 21, 2023 | msn.comMorgan Stanley Reiterates Intra-Cellular Therapies (ITCI) Overweight RecommendationSee More Headlines ITCI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITCI Company Calendar Last Earnings5/04/2023Today6/06/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees512Year FoundedN/APrice Target and Rating Average Stock Price Forecast$74.82 High Stock Price Forecast$98.00 Low Stock Price Forecast$49.00 Forecasted Upside/Downside+17.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-256,260,000.00 Net Margins-73.46% Pretax Margin-73.46% Return on Equity-33.92% Return on Assets-29.72% Debt Debt-to-Equity RatioN/A Current Ratio8.87 Quick Ratio8.52 Sales & Book Value Annual Sales$250.31 million Price / Sales24.22 Cash FlowN/A Price / Cash FlowN/A Book Value$6.93 per share Price / Book9.12Miscellaneous Outstanding Shares95,930,000Free Float92,665,000Market Cap$6.06 billion OptionableOptionable Beta1.13 Key ExecutivesSharon MatesChairman, President & Chief Executive OfficerLawrence J. HinelineChief Financial Officer, Treasurer & SVP-FinanceRobert E. DavisChief Scientific Officer & Senior Vice PresidentSuresh DurgamChief Medical Officer & Senior Vice PresidentKaren Patruno SheehyChief Compliance Officer & Senior Vice PresidentKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSGrifolsNASDAQ:GRFSIVERIC bioNASDAQ:ISEEMadrigal PharmaceuticalsNASDAQ:MDGLCerevel TherapeuticsNASDAQ:CEREView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 2,273 shares on 5/26/2023Ownership: 0.018%Toroso Investments LLCBought 3,980 shares on 5/23/2023Ownership: 0.004%Ameriprise Financial Inc.Bought 31,245 shares on 5/22/2023Ownership: 0.084%International Biotechnology Trust PLCBought 36,000 shares on 5/18/2023Ownership: 0.269%New York State Common Retirement FundSold 56,562 shares on 5/18/2023Ownership: 0.084%View All Insider TransactionsView All Institutional Transactions ITCI Stock - Frequently Asked Questions Should I buy or sell Intra-Cellular Therapies stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITCI shares. View ITCI analyst ratings or view top-rated stocks. What is Intra-Cellular Therapies' stock price forecast for 2023? 10 analysts have issued 12 month price targets for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $49.00 to $98.00. On average, they predict the company's stock price to reach $74.82 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price. View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts. How have ITCI shares performed in 2023? Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI shares have increased by 19.4% and is now trading at $63.21. View the best growth stocks for 2023 here. Are investors shorting Intra-Cellular Therapies? Intra-Cellular Therapies saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,560,000 shares, an increase of 21.9% from the April 30th total of 2,920,000 shares. Based on an average daily trading volume, of 893,600 shares, the days-to-cover ratio is currently 4.0 days. View Intra-Cellular Therapies' Short Interest. When is Intra-Cellular Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our ITCI earnings forecast. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings data on Thursday, May, 4th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.17. The biopharmaceutical company had revenue of $95.31 million for the quarter, compared to analysts' expectations of $92.14 million. Intra-Cellular Therapies had a negative net margin of 73.46% and a negative trailing twelve-month return on equity of 33.92%. What ETFs hold Intra-Cellular Therapies' stock? ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), AdvisorShares Psychedelics ETF (PSIL), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE), Innovator IBD Breakout Opportunities ETF (BOUT) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS). What is Intra-Cellular Therapies' stock symbol? Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI." Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (12.45%), BlackRock Inc. (7.58%), Wellington Management Group LLP (5.24%), Wasatch Advisors LP (4.67%), State Street Corp (2.11%) and JPMorgan Chase & Co. (1.91%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Intra-Cellular Therapies' stock price today? One share of ITCI stock can currently be purchased for approximately $63.21. How much money does Intra-Cellular Therapies make? Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $6.06 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. How many employees does Intra-Cellular Therapies have? The company employs 512 workers across the globe. How can I contact Intra-Cellular Therapies? Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334. This page (NASDAQ:ITCI) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.